ARQULE AND DAIICHI SANKYO ANNOUNCE DISCONTINUATION OF PHASE 3 MARQUEE CLINICAL TRIAL IN NON-SMALL CELL LUNG CANCER

[at noodls] – Contact: William B. Boni VP, Investor Relations/Corp. Communications ArQule, Inc. (781) 994-0300 www.ArQule.com Tara Camp Daiichi Sankyo, Inc. (US) (973) 944-2393 (908) 577-4531 Michaela Paudler-Debus, … more

View todays social media effects on ARQL

View the latest stocks trending across Twitter. Click to view dashboard